BioAgilytix Appoints Stephanie Hamilton as Global Lead, Virology — Expanding Global Virology Expertise  

Durham, NC – June 23, 2025— BioAgilytix, a leading global bioanalytical laboratory, is pleased to announce the appointment of Stephanie Hamilton as Global Lead, Virology. Based in Australia, Stephanie brings over 25 years of virology experience and has been a pivotal member of the BioAgilytix team for more than eight years. 

Stephanie’s expertise in virology assay development strengthens BioAgilytix’s ability to support complex bioanalytical needs across the company’s global footprint, including expansions in viral vectors, antiviral drugs, and infectious disease therapies. Under her leadership and leveraging the specialized virology expertise from 360biolabs, a BioAgilytix company, our global virology services will continue to advance, ensuring high-quality solutions for clients worldwide. 

BioAgilytix offers comprehensive virology services, including classical techniques such as plaque assays and viral neutralization assays, as well as advanced molecular methods such as quantitative PCR (qPCR) and digital PCR (dPCR). BioAgilytix evaluates both humoral and cellular immunogenicity endpoints using plate-based ELISA, MSD platforms, and ELISpot assays. With BSL-2 laboratories in the United States and Europe and BSL-3 laboratories in Australia, the company handles a wide range of viral agents in compliance with global regulatory standards.  

Under Stephanie’s leadership, BioAgilytix is expanding and harmonizing its virology services globally. This appointment reflects the company’s broader strategy to deliver harmonized scientific excellence and operational consistency across all regions. 

“Stephanie has been instrumental in delivering high-quality virology support to our clients, and we are thrilled to see her step into this leadership role,” said Davide Molho, CEO of BioAgilytix. “Her scientific depth, combined with her strategic location in Australia, strengthens our ability to serve clients globally—especially those looking to accelerate early-phase development through Australia’s regulatory advantages.” 

Since 2021, BioAgilytix has supported more than 100 virology-focused studies and developed over 100 assays for clients worldwide, underscoring its proven track record in advancing innovative therapies. 

Stephanie’s appointment reinforces BioAgilytix’s commitment to scientific leadership in virology and bioanalysis. With labs in the United States, Europe, and Australia, the company is poised to advance innovative therapies worldwide. 

About BioAgilytix 

BioAgilytix is the trusted partner for bioanalytical services throughout every phase of the drug development process. As a leading global bioanalytical laboratory, the company provides established and emerging pharmaceutical and biotechnology organizations with pharmacokinetic (PK), immunogenicity, biomarker, and CMC analytical testing services in a GxP environment. BioAgilytix maintains state-of-the-art laboratories in Durham, North Carolina; Boston, Massachusetts; San Diego, California; Melbourne and Brisbane, Australia; and Hamburg, Germany. For more information, please visit www.bioagilytix.com.